Qualigen Therapeutics, Inc. Receives Notification of Deficiency from Nasdaq Related to Delayed Filing of Annual Report on Form 10-K

Core Points - Qualigen Therapeutics, Inc. received a deficiency notification from Nasdaq for failing to timely file its Annual Report on Form 10-K for the year ended December 31, 2024 [1] - A Nasdaq Hearings Panel imposed a Discretionary Panel Monitor, which could lead to a Delist Determination Letter if compliance is not maintained [2] - The company intends to appeal the delisting decision and is working to regain compliance with Nasdaq's listing rules [3] Filing Delays - The delay in filing the 2024 Form 10-K was due to the need for the company to complete its accounting and internal control processes [4] - The company is committed to filing the 2024 Form 10-K as soon as practicable, although no specific timeline can be assured [4]